Joseph Raker's Colleagues at Immunophotonics Inc
Joseph Raker's Contact Details
N/A
Immunophotonics Inc
Joseph Raker's Company Details
Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.